170277-31-3
基本信息
INFLIXIMAB ( 英利昔單抗 )
CT-P 13
Remicade
Unii-B72hh48flu
Infliximab USP/EP/BP
Immunoglobulin G, anti-(human tumor necrosis factor) (human-mouse monoclonal ca2 heavy chain), disulfide with human-mouse monoclonal ca2 light chain, dimer
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/03/03 | A2019 | 英夫利昔單抗 Infliximab (anti-TNF-alpha) | 170277-31-3 | 1mg | 3022.19元 |
| 2026/03/03 | A2019 | 英夫利昔單抗 Infliximab (anti-TNF-alpha) | 170277-31-3 | 5mg | 8919.91元 |
| 2026/03/03 | A2019 | 英夫利昔單抗 Infliximab (anti-TNF-alpha) | 170277-31-3 | 1mg*5 | 8919.91元 |
常見問題列表
|
TNF-α
|
TNF-α-treated adipocytes shows a significant 64% decrease in insulin-stimulated glucose uptake, whereas Infliximab (10 ng/mL) reverses TNF-α actions by significantly improving glucose incorporation in 3T3L1 adipocytes. Infliximab restores phosphorylation of substrate-2 and AKT by attenuating protein-tyrosine phosphatase 1B (PTP1B) activation. Infliximab ameliorates TNF-α-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition.
A single injection of Infliximab (10 μg/g in 100 μl saline/dose ip) in diabetic TNF-α +/+ ) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 weeks. The increased TNF-α mRNA expression in diabetic dorsal root ganglion is also attenuated by Infliximab.